Literature DB >> 7112506

Studies on a highly active anticoagulant fraction of high molecular weight isolated from porcine sodium heparin.

E Sache, M Maillard, H Bertrand, M Maman, M Kunz, J Choay, J Fareed, H Messmore.   

Abstract

We have studied heparin fractionation using gel filtration and ion-exchange chromatographic methods. The starting material was commercial grade porcine mucosal sodium heparin (PSH). The fractionation was monitored employing synthetic substrates for assaying both antithrombin (with H-D-Phe-Pip-Arg-pNA ; S-2238) and anti-FXa (with Bz-Ileu-Glu-Gly-Arg-pNA ; S-2222) activities. The resulting fractions were evaluated in different amidolytic and coagulation methods used to determine heparin potency by comparison with PSH. By gel filtration of PSH on Ultrogel Aca 54, both strong anti-FXa and antithrombin activities were associated with the fractions eluted in the high molecular weight range (MW congruent to 20 x 10(3)). These fractions also had potent anticoagulant action when assayed by conventional clotting methods. PSH was also subjected to fractionation by an ion-exchange technique (DEAE-Sephacel) with increasing salt molarity. The patterns for antithrombin and anti-FXa activities were again closely related, if not identical. Four fractions were usually distinguished, with respectively negligible, intermediate, high and very high activities when compared to PSH. The very highly active fraction (HAF), approximately 15% by weight, was eluted at high salt molarity (greater than 0.8 M NaCl). On a weight basis its anticoagulant activity was congruent to 2-3 times that of PSH as determined by amidolytic as well as clotting methods. Intravenous injection of HAF to rabbits and dogs (1.0 and 2.5 mg/kg) produced a much stronger anticoagulant response than PSH, also showing an effect which persisted for a longer duration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7112506     DOI: 10.1016/0049-3848(82)90086-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

1.  The heparin-catalysed inhibition of human factor XIa by antithrombin III is dependent on the heparin type.

Authors:  H Soons; G Tans; H C Hemker
Journal:  Biochem J       Date:  1988-12-15       Impact factor: 3.857

2.  Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

Authors:  P J Hogg; C M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

3.  Endothelial binding sites for heparin. Specificity and role in heparin neutralization.

Authors:  T Bârzu; J L Van Rijn; M Petitou; P Molho; G Tobelem; J P Caen
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

4.  Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group.

Authors:  J J Castellot; J Choay; J C Lormeau; M Petitou; E Sache; M J Karnovsky
Journal:  J Cell Biol       Date:  1986-05       Impact factor: 10.539

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.